Consider Lixiana for Patients Who Want a Once-Daily Direct Oral Anticoagulant

Lixiana (LIKS-ee-ah-nah, edoxaban) will be the fourth direct oral anticoagulant (DOAC)...after Eliquis, Pradaxa, and Xarelto.

Lixiana is approved to reduce stroke risk due to atrial fib...and to treat venous thromboembolism (VTE).

It's marketed in the U.S. under the brand name Savaysa.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote